Storia in 3 fonti

Genmab/AbbVie Lymphoma Trial Meets Main Goal, Analyst Eyes Bigger Market Opportunity - AbbVie (NYSE:ABBV)

Genmab reports positive Phase 3 EPCORE DLBCL-4 results in relapsed lymphoma; analyst points to label expansion and future growth opportunities.

Raccontata da

morningstar.com

benzinga.com

fiercepharma.com

Confronto fonti

3 prospettive sulla stessa storia

AI · summaries

benzinga.comStai leggendo16 h fa

Genmab/AbbVie Lymphoma Trial Meets Main Goal, Analyst Eyes Bigger Market Opportunity - AbbVie (NYSE:ABBV)

Genmab reports positive Phase 3 EPCORE DLBCL-4 results in relapsed lymphoma; analyst points to label expansion and future growth opportunities.

originale

morningstar.com1 g fa

Genmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with…

Genmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Demonstrating Statistically Significant Improvement in Progression-Free…

Leggi questa versione →

Timeline cronologica

lunedì 29 giugno 2026·morningstar.com
Genmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell…
Genmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Demonstrating Statistically…
lunedì 29 giugno 2026·morningstar.com
AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell…

Genmab/AbbVie Lymphoma Trial Meets Main Goal, Analyst Eyes Bigger Market Opportunity - AbbVie (NYSE:ABBV)

Confronto fonti

Genmab/AbbVie Lymphoma Trial Meets Main Goal, Analyst Eyes Bigger Market Opportunity - AbbVie (NYSE:ABBV)

Genmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with…

Timeline cronologica

Genmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell…

AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell…

After monotherapy failure, AbbVie and Genmab tout Epkinly combo win in DLBCL

AbbVie Reports Phase 3 EPCORE DLBCL-4 Results Showing Epcoritamab Combination Reduced Disease Progression

After monotherapy failure, AbbVie and Genmab tout Epkinly combo win in DLBCL

Genmab/AbbVie Lymphoma Trial Meets Main Goal, Analyst Eyes Bigger Market Opportunity - AbbVie (NYSE:ABBV)